Affordable Access

deepdyve-link
Publisher Website

The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.

Authors
  • Somm, Emmanuel1
  • Montandon, Sophie A2
  • Loizides-Mangold, Ursula3
  • Gaïa, Nadia4
  • Lazarevic, Vladimir4
  • De Vito, Claudio5
  • Perroud, Elodie2
  • Bochaton-Piallat, Marie-Luce6
  • Dibner, Charna3
  • Schrenzel, Jacques7
  • Jornayvaz, François R8
  • 1 Service of Endocrinology, Diabetes, Nutrition and Patient Education, Department of Internal Medicine, Geneva University Hospitals/University of Geneva, Geneva, Switzerland; Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: [email protected] , (Switzerland)
  • 2 Service of Endocrinology, Diabetes, Nutrition and Patient Education, Department of Internal Medicine, Geneva University Hospitals/University of Geneva, Geneva, Switzerland; Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland. , (Switzerland)
  • 3 Service of Endocrinology, Diabetes, Nutrition and Patient Education, Department of Internal Medicine, Geneva University Hospitals/University of Geneva, Geneva, Switzerland; Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland; Institute of Genetics and Genomics in Geneva (iGE3), University of Geneva, Geneva, Switzerland. , (Switzerland)
  • 4 Genomic Research Laboratory, Service of Infectious Diseases, Geneva University Hospitals, University of Geneva, Geneva, Switzerland. , (Switzerland)
  • 5 Division of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland. , (Switzerland)
  • 6 Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. , (Switzerland)
  • 7 Genomic Research Laboratory, Service of Infectious Diseases, Geneva University Hospitals, University of Geneva, Geneva, Switzerland; Bacteriology Laboratory, Service of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland. , (Switzerland)
  • 8 Service of Endocrinology, Diabetes, Nutrition and Patient Education, Department of Internal Medicine, Geneva University Hospitals/University of Geneva, Geneva, Switzerland; Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: [email protected] , (Switzerland)
Type
Published Article
Journal
Translational research : the journal of laboratory and clinical medicine
Publication Date
Jan 01, 2021
Volume
227
Pages
75–88
Identifiers
DOI: 10.1016/j.trsl.2020.07.008
PMID: 32711187
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disorder related to type 2 diabetes (T2D). The disease can evolve toward nonalcoholic steatohepatitis (NASH), a state of hepatic inflammation and fibrosis. There is presently no drug that effectively improves and/or prevents NAFLD/NASH/fibrosis. GLP-1 receptor agonists (GLP-1Ra) are effective in treating T2D. As with the endogenous gut incretins, GLP-1Ra potentiate glucose-induced insulin secretion. In addition, GLP-1Ra limit food intake and weight gain, additional beneficial properties in the context of obesity/insulin-resistance. Nevertheless, these pleiotropic effects of GLP-1Ra complicate the elucidation of their direct action on the liver. In the present study, we used the classical methionine-choline deficient (MCD) dietary model to investigate the potential direct hepatic actions of the GLP-1Ra liraglutide. A 4-week infusion of liraglutide (570 µg/kg/day) did not impact body weight, fat accretion or glycemic control in MCD-diet fed mice, confirming the suitability of this model for avoiding confounding factors. Liraglutide treatment did not prevent lipid deposition in the liver of MCD-fed mice but limited the accumulation of C16 and C24-ceramide/sphingomyelin species. In addition, liraglutide treatment alleviated hepatic inflammation (in particular accumulation of M1 pro-inflammatory macrophages) and initiation of fibrosis. Liraglutide also influenced the composition of gut microbiota induced by the MCD-diet. This included recovery of a normal Bacteroides proportion and, among the Erysipelotrichaceae family, a shift between Allobaculum and Turicibacter genera. In conclusion, liraglutide prevents accumulation of C16 and C24-ceramides/sphingomyelins species, inflammation and initiation of fibrosis in MCD-diet-fed mice liver, suggesting beneficial hepatic actions independent of weight loss and global hepatic steatosis. Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times